Parkman Healthcare Partners is an investment fund managing more than $460 billion ran by Michael Elgort. There are currently 83 companies in Mr. Elgort’s portfolio. The largest investments include United Therapeutics Corp and Neurocrine Biosciences, together worth $46.3 billion.
Limited to 30 biggest holdings
$460 billion Assets Under Management (AUM)
As of 5th May 2023, Parkman Healthcare Partners’s top holding is 108,072 shares of United Therapeutics Corp currently worth over $24.2 billion and making up 5.3% of the portfolio value.Relative to the number of outstanding shares of United Therapeutics Corp, Parkman Healthcare Partners owns more than approximately 0.1% of the company.In addition, the fund holds 217,838 shares of Neurocrine Biosciences worth $22 billion, whose value fell approximately 0.1% in the past six months. The third-largest holding is Boston Scientific worth $21.4 billion and the next is Cooper Cos Inc worth $19.6 billion, with 52,384 shares owned.
Currently, Parkman Healthcare Partners's portfolio is worth at least $460 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Parkman Healthcare Partners
The Parkman Healthcare Partners office and employees reside in Stamford, Connecticut. According to the last 13-F report filed with the SEC, Michael Elgort serves as the CHIEF FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER at Parkman Healthcare Partners.
